Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
NEW YORK, Dec. 08, 2016 -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Allergan plc (NYSE:AGN) and/or Actavis plc between February 25, 2014 and November 3, 2016, both dates inclusive (the “Class Period”). The lawsuit seeks recovery of investor losses.
To join the Allergan class action, go to http://www.rosenlegal.com/cases-980.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) Allergan and Actavis were engaging and/or had engaged in conduct that would result in an antitrust investigation by the U.S. Department of Justice; (2) the DOJ investigation and the underlying conduct could cause U.S. prosecutors to file criminal charges against Allergan and Actavis by the end of 2016 for suspected price collusion; (3) in turn, Allergan and Actavis lacked effective internal controls; and (4) as a result, Allergan plc’s and Actavis plc’s public statements were materially false and misleading at all relevant times.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 3, 2017. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-980.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com
